+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market by Treatment Class, Administration Route, Distribution Channel, End User, Therapy Line - Global Forecast to 2030- Product Image
Myasthenia Gravis Treatment Market by Treatment Class, Administration Route, Distribution Channel, End User, Therapy Line - Global Forecast to 2030- Product Image
Sale

Myasthenia Gravis Treatment Market by Treatment Class, Administration Route, Distribution Channel, End User, Therapy Line - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674103
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The myasthenia gravis treatment market is evolving rapidly, shaped by clinical innovation and the need for strategic agility among leading stakeholders. Senior leaders face a dynamic environment that spans regulatory shifts, patient-centric care, and emerging therapies reshaping standards for disease management. This report provides actionable insights into the competitive landscape and essential factors driving market growth.

Market Snapshot: Myasthenia Gravis Treatment Market

The myasthenia gravis treatment market grew from USD 2.00 billion in 2024 to USD 2.11 billion in 2025. It is projected to continue expanding at a CAGR of 5.48%, reaching USD 2.76 billion by 2030. Established therapies coexist with cutting-edge biologics and precision medicines as care models transition toward tailored patient management and value-based decisions. Market participants are adapting to new reimbursement structures and regulatory frameworks, ensuring the sustained evolution of therapeutic portfolios and regional access models.

Scope & Segmentation

This report delivers an in-depth analysis across the following critical dimensions:

  • Treatment Classes: Acetylcholinesterase inhibitors, corticosteroids, nonsteroidal immunosuppressants (including azathioprine, cyclosporine, mycophenolate mofetil), intravenous immunoglobulin, monoclonal antibodies (eculizumab, ravulizumab, rituximab), plasma exchange.
  • Administration Routes: Intravenous, oral, subcutaneous.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • End Users: Clinics, home care, hospitals.
  • Therapy Lines: First line, refractory, second line.
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (covering the United Kingdom, Germany, France, Italy, Spain, among others), and Asia-Pacific (notably China, India, Japan, Australia, South Korea, and more).
  • Top Manufacturers: Alexion Pharmaceuticals, argenx SE, UCB S.A., Takeda, Sanofi, Johnson & Johnson, Pfizer, Novartis, CSL Limited, Roche.

Key Takeaways for Decision Makers

  • Advanced biologics and precision therapies are altering treatment pathways, particularly for patients with refractory or inadequately managed myasthenia gravis.
  • Immunosuppressants, including nonsteroidal agents, maintain stable demand due to established clinical guidelines and long-term efficacy profiles.
  • Emerging subcutaneous and digital health-enabled solutions are improving patient adherence and expanding care outside traditional hospital settings, driving market differentiation.
  • Distribution partnerships and digital fulfillment platforms are supporting complex therapy delivery—especially for home administration and specialty clinic use.
  • Real-world data initiatives and value-based contracting are becoming pivotal for pricing strategies and market access negotiations across global regions.
  • Industry leaders are responding to evolving trade landscapes and supply chain disruptions by reassessing manufacturing footprints and contract structures.

Tariff Impact and Supply Chain Dynamics

The upcoming United States tariffs in 2025 mark a crucial juncture for the cost structure and security of myasthenia gravis therapy supply. With several cornerstone treatments relying on imported active pharmaceutical ingredients, revised tariff policies are placing upward pricing pressure throughout procurement and reimbursement channels. Manufacturers are exploring local production and flexible sourcing to mitigate exposure, although transitions to new facilities may introduce short-term supply and pricing challenges.

Methodology & Data Sources

This research employs a rigorous approach combining primary interviews with key opinion leaders, neurologists, and pharmacists, alongside secondary analysis of industry reports, regulatory filings, and clinical trial registries. Data triangulation ensures reliability, while structured quality control validates the accuracy of findings across segments, geographies, and technologies.

Why This Report Matters

  • Provides clear, actionable guidance for executive decision-making on portfolio strategy, partnership development, and resource allocation.
  • Offers critical evaluation of the tariff landscape, supply risks, and innovative technologies to support resilience planning and sustainable market entry or expansion.
  • Delivers objective, thoroughly validated data to underpin negotiations with payers, regulators, and distribution partners.

Conclusion

The myasthenia gravis treatment landscape is undergoing significant transformation, demanding strategic foresight and operational flexibility from industry stakeholders. Market insight, combined with scenario-based planning and focused partnerships, will define leadership and unlock long-term value in this evolving sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Myasthenia Gravis Treatment Market, by Treatment Class
8.1. Introduction
8.2. Acetylcholinesterase Inhibitors
8.3. Immunosuppressants
8.3.1. Corticosteroids
8.3.2. Nonsteroidal Immunosuppressants
8.3.2.1. Azathioprine
8.3.2.2. Cyclosporine
8.3.2.3. Mycophenolate Mofetil
8.4. Intravenous Immunoglobulin
8.5. Monoclonal Antibodies
8.5.1. Eculizumab
8.5.2. Ravulizumab
8.5.3. Rituximab
8.6. Plasma Exchange
9. Myasthenia Gravis Treatment Market, by Administration Route
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Myasthenia Gravis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Myasthenia Gravis Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Myasthenia Gravis Treatment Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Refractory
12.4. Second Line
13. Americas Myasthenia Gravis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Myasthenia Gravis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Myasthenia Gravis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alexion Pharmaceuticals, Inc.
16.3.2. argenx SE
16.3.3. UCB S.A.
16.3.4. Takeda Pharmaceutical Company Limited
16.3.5. Sanofi S.A.
16.3.6. Johnson & Johnson
16.3.7. Pfizer Inc.
16.3.8. Novartis AG
16.3.9. CSL Limited
16.3.10. Roche Holding AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. MYASTHENIA GRAVIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 58. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 59. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 60. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 61. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 62. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 69. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 118. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 130. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 131. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 132. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 133. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 134. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 135. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 142. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 170. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 174. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 175. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 186. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 187. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 188. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 189. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 191. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 198. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 230. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 246. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 250. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 251. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 252. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 253. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 255. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 275. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 276. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 277. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 278. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 280. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 283. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 284. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 285. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 286. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 288. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 295. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Myasthenia Gravis Treatment market report include:
  • Alexion Pharmaceuticals, Inc.
  • argenx SE
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • CSL Limited
  • Roche Holding AG

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.76 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 230 Pages
  • Global
From
Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Myasthenia Gravis Treatment Market Report 2025 - Product Image

Myasthenia Gravis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myasthenia Gravis Drugs - Global Strategic Business Report - Product Image

Myasthenia Gravis Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From

About the Myasthenia Gravis Drug Market

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. MG is treated with a variety of drugs, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Anticholinesterase drugs, such as pyridostigmine, are used to increase the availability of acetylcholine at the neuromuscular junction, thereby improving muscle strength. Immunosuppressants, such as azathioprine and cyclosporine, are used to reduce the production of antibodies that attack the neuromuscular junction. Immunomodulators, such as mycophenolate mofetil, are used to modulate the immune system and reduce the production of antibodies. The Myasthenia Gravis Drug market is a subset of the Central Nervous System Drugs market. It is composed of a variety of drugs used to treat MG, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Companies in the Myasthenia Gravis Drug market include Merck, Pfizer, Novartis, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.